Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 366

1.
2.
3.

TGFbeta/activin/nodal signaling is necessary for the maintenance of pluripotency in human embryonic stem cells.

James D, Levine AJ, Besser D, Hemmati-Brivanlou A.

Development. 2005 Mar;132(6):1273-82. Epub 2005 Feb 9.

4.

Transforming growth factor-beta- and Activin-Smad signaling pathways are activated at distinct maturation stages of the thymopoeisis.

Rosendahl A, Speletas M, Leandersson K, Ivars F, Sideras P.

Int Immunol. 2003 Dec;15(12):1401-14.

PMID:
14645149
5.

Activin receptor-like kinase-7 induces apoptosis through activation of MAPKs in a Smad3-dependent mechanism in hepatoma cells.

Kim BC, van Gelder H, Kim TA, Lee HJ, Baik KG, Chun HH, Lee DA, Choi KS, Kim SJ.

J Biol Chem. 2004 Jul 2;279(27):28458-65. Epub 2004 Apr 23.

6.

The orphan receptor serine/threonine kinase ALK7 signals arrest of proliferation and morphological differentiation in a neuronal cell line.

Jörnvall H, Blokzijl A, ten Dijke P, Ibáñez CF.

J Biol Chem. 2001 Feb 16;276(7):5140-6. Epub 2000 Nov 17.

7.

SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7.

Inman GJ, Nicolás FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ, Hill CS.

Mol Pharmacol. 2002 Jul;62(1):65-74.

8.

Nodal signaling uses activin and transforming growth factor-beta receptor-regulated Smads.

Kumar A, Novoselov V, Celeste AJ, Wolfman NM, ten Dijke P, Kuehn MR.

J Biol Chem. 2001 Jan 5;276(1):656-61.

9.
10.

Selective inhibition of activin receptor-like kinase 5 signaling blocks profibrotic transforming growth factor beta responses in skin fibroblasts.

Mori Y, Ishida W, Bhattacharyya S, Li Y, Platanias LC, Varga J.

Arthritis Rheum. 2004 Dec;50(12):4008-21.

11.

A component of the ARC/Mediator complex required for TGF beta/Nodal signalling.

Kato Y, Habas R, Katsuyama Y, Näär AM, He X.

Nature. 2002 Aug 8;418(6898):641-6. Epub 2002 Jul 24.

PMID:
12167862
12.

Transforming growth factor-beta-mediated chondrogenesis of human mesenchymal progenitor cells involves N-cadherin and mitogen-activated protein kinase and Wnt signaling cross-talk.

Tuli R, Tuli S, Nandi S, Huang X, Manner PA, Hozack WJ, Danielson KG, Hall DJ, Tuan RS.

J Biol Chem. 2003 Oct 17;278(42):41227-36. Epub 2003 Jul 31.

13.

Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.

Subramanian G, Schwarz RE, Higgins L, McEnroe G, Chakravarty S, Dugar S, Reiss M.

Cancer Res. 2004 Aug 1;64(15):5200-11.

14.

Engagement of activin and bone morphogenetic protein signaling pathway Smad proteins in the induction of inhibin B production in ovarian granulosa cells.

Bondestam J, Kaivo-oja N, Kallio J, Groome N, Hydén-Granskog C, Fujii M, Moustakas A, Jalanko A, ten Dijke P, Ritvos O.

Mol Cell Endocrinol. 2002 Sep 30;195(1-2):79-88.

PMID:
12354674
15.
16.

Functional analysis of the TGFbeta receptor/Smad pathway through gene ablation in mice.

Goumans MJ, Mummery C.

Int J Dev Biol. 2000 Apr;44(3):253-65. Review.

17.

Molecular analysis of LEFTY-expressing cells in early human embryoid bodies.

Dvash T, Sharon N, Yanuka O, Benvenisty N.

Stem Cells. 2007 Feb;25(2):465-72. Epub 2006 Oct 12.

19.

SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7.

DaCosta Byfield S, Major C, Laping NJ, Roberts AB.

Mol Pharmacol. 2004 Mar;65(3):744-52.

20.

Phosphorylation regulation of the interaction between Smad7 and activin type I receptor.

Liu X, Nagarajan RP, Vale W, Chen Y.

FEBS Lett. 2002 May 22;519(1-3):93-8.

Supplemental Content

Support Center